Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Affimed N.V. (AFMD)

Affimed N.V. (AFMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 90,296
  • Shares Outstanding, K 15,227
  • Annual Sales, $ 8,960 K
  • Annual Income, $ -114,660 K
  • 60-Month Beta 2.04
  • Price/Sales 9.98
  • Price/Cash Flow N/A
  • Price/Book 2.04
Trade AFMD with:

Options Overview Details

View History
  • Implied Volatility 112.30% ( +2.78%)
  • Historical Volatility 167.45%
  • IV Percentile 17%
  • IV Rank 8.00%
  • IV High 1,342.71% on 11/14/23
  • IV Low 5.31% on 02/15/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 926
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 9,774
  • Open Int (30-Day) 8,246

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -1.00
  • Number of Estimates 4
  • High Estimate -0.52
  • Low Estimate -1.26
  • Prior Year -2.20
  • Growth Rate Est. (year over year) +54.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.80 +53.16%
on 05/29/24
8.95 -34.97%
on 06/12/24
+1.63 (+38.90%)
since 05/24/24
3-Month
3.80 +53.16%
on 05/29/24
8.95 -34.97%
on 06/12/24
+0.63 (+12.14%)
since 03/25/24
52-Week
2.23 +160.40%
on 10/27/23
8.95 -34.97%
on 06/12/24
-0.68 (-10.50%)
since 06/23/23

Most Recent Stories

More News
Affimed N.V.: Q1 Earnings Snapshot

Affimed N.V.: Q1 Earnings Snapshot

AFMD : 5.86 (-1.18%)
Affimed N.V.: Q3 Earnings Snapshot

Affimed N.V.: Q3 Earnings Snapshot

AFMD : 5.86 (-1.18%)
Affimed N.V.: Q2 Earnings Snapshot

Affimed N.V.: Q2 Earnings Snapshot

AFMD : 5.86 (-1.18%)
Affimed N.V.: Q1 Earnings Snapshot

Affimed N.V.: Q1 Earnings Snapshot

AFMD : 5.86 (-1.18%)
Why Shares of Affimed Fell Thursday

The clinical-stage biotech focuses on immuno-oncology therapies.

AFMD : 5.86 (-1.18%)
Affimed N.V.: Q3 Earnings Snapshot

Affimed N.V.: Q3 Earnings Snapshot

AFMD : 5.86 (-1.18%)
Why Affimed Stock Plummeted by Over 16% Today

An analyst's downgrade brings out the bears for the European cancer treatment developer.

AFMD : 5.86 (-1.18%)
SF : 81.04 (-0.17%)
Billionaires Are Scooping Up These 3 Beaten-Down Biotech Stocks

This billionaire-guided hedge fund went bargain-shopping in the second quarter.

AFMD : 5.86 (-1.18%)
CERS : 1.6900 (unch)
REPL : 8.86 (+1.14%)
Affimed Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Progress

AFM13 monotherapy: On track to report topline data of the registration-directed REDIRECT trial in the fourth quarter of 2022AFM13 combination with natural...

AFMD : 5.86 (-1.18%)
Affimed to Report Second Quarter 2022 Financial Results & Corporate Update on August 11, 2022

HEIDELBERG, Germany, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology...

AFMD : 5.86 (-1.18%)

Business Summary

Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V.,...

See More

Key Turning Points

3rd Resistance Point 6.62
2nd Resistance Point 6.43
1st Resistance Point 6.18
Last Price 5.86
1st Support Level 5.74
2nd Support Level 5.55
3rd Support Level 5.30

See More

52-Week High 8.95
Fibonacci 61.8% 6.38
Last Price 5.86
Fibonacci 50% 5.59
Fibonacci 38.2% 4.80
52-Week Low 2.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar